Lv5
1145 积分 2022-03-31 加入
Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies
1个月前
已完结
Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression
1个月前
已完结
Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors
1个月前
已关闭
Targeting STING to generate therapeutic anti-tumor immunity
1个月前
已完结
IL‐12 and the Antitumor Response: The Good, the Bad, and the Unknown
1个月前
已完结
Integrin α11: Key Signaling Pathways and Tumor Dynamics
2个月前
已完结
Endosialin (CD248) Cancer Role and Therapeutics: 33 years on
2个月前
已完结
In Vivo Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
3个月前
已关闭
Reprogramming the tumor immune microenvironment via antibody-drug conjugates
3个月前
已完结
Abstract 5567:In vivoadministration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors
3个月前
已关闭
皖公网安备34019202002308
